Eptinezumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Eptinezumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target CALCA, CALCB
Clinical data
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6352H9838N1694O1992S46
Molar mass 143.2 g/mol

Eptinezumab (formerly ALD403[1]) is an experimental drug being developed by Alder Biopharmaceuticals for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.[2][3] It is in Phase III clinical trials as of August 2017.[4]

See also[edit]

References[edit]

  1. ^ http://investor.alderbio.com/releasedetail.cfm?releaseid=1001091
  2. ^ Dodick, David W; Goadsby, Peter J; Silberstein, Stephen D; Lipton, Richard B; Olesen, Jes; Ashina, Messoud; Wilks, Kerri; Kudrow, David; Kroll, Robin; Kohrman, Bruce; Bargar, Robert; Hirman, Joe; Smith, Jeff (2014). "Safety and efficacy of eptinizumab, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet Neurology. 13 (11): 1100. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013.
  3. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 31 (1). 2017.
  4. ^ "Pipeline". Alder Biopharmaceuticals.